The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

On this week's Business of Biotech episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for ...

Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration ...

Host Erin Harris talks to Generate:Biomedicines' EVP of R&D, Dr. Alex Snyder on Cell & Gene: The Podcast about the convergence of AI, machine learning (ML), and synthetic biology in the development of ...

Clinical trial system builds have long been plagued by inefficiencies, miscommunications, and long timelines—often described by sponsors and CROs as a “black box” process where outcomes misalign with ...

On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech ...

Earnouts have been a part of M&A for decades, with pharmaceutical M&A transactions in particular relying on them. These earnout provisions are typically referred to as “milestone payments” because ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...